| Trial ID: | L2187 |
| Source ID: | NCT00188773
|
| Associated Drug: |
N-Acetylcysteine, Intralipid, Heparin
|
| Title: |
Mechanism of Fatty Acid-Induced Impairment of Glucose-Stimulated Insulin Secretion
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Insulin Resistance Syndrome X|Pancreatic Beta Cell Function
|
| Interventions: |
DRUG: N-acetylcysteine, intralipid, heparin
|
| Outcome Measures: |
Primary: To determine whether the FFA-induced impairment of pancreatic b-cell function can be ameliorated or prevented by administration of the antioxidant, NAC, 2 years|Assessment of insulin sensitivity, 2 years|To determine whether administration of NAC, an antioxidant, prevents FFA-mediated impairment of GSIS in healthy humans., 2 years | Secondary: assessment of glucose stimulated insulin secretion, 2 years
|
| Sponsor/Collaborators: |
Sponsor: University Health Network, Toronto
|
| Gender: |
MALE
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
15
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC
|
| Start Date: |
2004-01
|
| Completion Date: |
2008-01
|
| Results First Posted: |
|
| Last Update Posted: |
2008-06-05
|
| Locations: |
University Health Network, Toronto, Ontario, M5G 2C4, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT00188773
|
